Pseudomonas aeruginosa is problematic in healthcare due to its high antibiotic resistance, highlighting the need for new antimicrobial solutions.
A study focused on isolating a new bacteriocin from Enterococcus faecium found in stool samples, which showed promise against multidrug-resistant P. aeruginosa.
The purified bacteriocin, enterocin GH, demonstrated significant antibacterial and antibiofilm activity against P. aeruginosa, outperforming controls in laboratory tests.